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Abstract
Biotin is an essential vitamin that binds streptavidin or avidin with high affinity and specificity. As biotin is a small molecule
that can be linked to proteins without affecting their biological activity, biotinylation is applied widely in biochemical assays.
In our laboratory, IgM enzyme immuno assays (EIAs) of m-capture format have been set up against many viruses, using as
antigen biotinylated virus like particles (VLPs) detected by horseradish peroxidase-conjugated streptavidin. We recently
encountered one serum sample reacting with the biotinylated VLP but not with the unbiotinylated one, suggesting in
human sera the occurrence of biotin-reactive antibodies. In the present study, we search the general population (612 serum
samples from adults and 678 from children) for IgM antibodies reactive with biotin and develop an indirect EIA for
quantification of their levels and assessment of their seroprevalence. These IgM antibodies were present in 3% adults
regardless of age, but were rarely found in children. The adverse effects of the biotin IgM on biotinylation-based
immunoassays were assessed, including four inhouse and one commercial virus IgM EIAs, showing that biotin IgM do cause
false positivities. The biotin can not bind IgM and streptavidin or avidin simultaneously, suggesting that these biotin-
interactive compounds compete for the common binding site. In competitive inhibition assays, the affinities of biotin IgM
antibodies ranged from 2.161023 to 1.761024 mol/L. This is the first report on biotin antibodies found in humans,
providing new information on biotinylation-based immunoassays as well as new insights into the biomedical effects of
vitamins.
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Introduction
Biotin, also known as vitamin B7 and vitamin H, is a water-
soluble micronutrient required by most organisms. In mammals,
biotin acts as a coenzyme for four carboxylases: propionyl-
coenzyme A (CoA) carboxylase, pyruvate carboxylase, methylcro-
tonoyl-CoA carboxylase, and acetyl-CoA carboxylase. The first
three are located in mitochondria and the fourth in the cytoplasm.
These enzymes catalyze critical reactions in the intermediary
metabolism of gluconeogenesis, fatty acid synthesis, and amino
acid catabolism [1,2]. Therefore, insufficient biotin intake may
lead to a number of clinical abnormalities, including hair loss,
dermal rash, growth retardation, neurological disorders and
a higher vulnerability to infections [1,3–5].
Biotin deficiency is rare among constitutionally healthy people
as this nutrient is widely distributed in foods and also amply
synthesized by the intestinal flora, meeting with our low daily
requirement (approximately15–70 mg/day) [1,2]. However, biotin
deficiency can ensue upon excessive consumption of raw eggs, due
to its constituent, avidin, binding biotin at high affinity in the
alimentary tract, and preventing its intestinal absorption [3,6–8].
In the human body, only free biotin can function in metabolism,
whereas most of the dietary biotin is protein-bound [2].
Biotinidase, a hepatic enzyme synthesized in the liver and secreted
into the blood, is responsible for processing protein-bound biotin
and recycling biotin [5,9]. In human serum, biotin circulates in
free form or protein-bound, for uptake by cells and tissues
including liver cells, cerebral capillaries, basolateral membrane
vesicles of placenta, and peripheral blood mononuclear cells [1,2].
Due to its small size, biotin can be covalently linked to a number
of proteins without affecting their biological activity. As biotin
binds avidin or streptavidin with extremely high affinity and
specificity, biotinylation of proteins and macromolecules is applied
widely in biochemical assays [10–14]. In our laboratory, for
detecting IgM antibodies against many different viruses, m-capture
enzyme immuno assays (EIAs) have been set up by using as
antigen biotinylated virus like particles (VLPs) detected by
horseradish peroxidase (HRP)-conjugated streptavidin [15–18].
As the presence of pathogen-specific IgM antibody is applied as
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a marker of ongoing or recent infection, the specificity of the assay
is critically important. We recently, aiming at employing as
a negative control in our Merkel cell polyomavirus (MCV) IgM
serology, and encountering strong reactivity in the serum of one of
us authors, found the IgM to react with the biotinylated VLPs but
not with the unbiotinylated ones. Prompted by this preliminary
finding, the following study was initiated.
In this study, we looked for human serum IgM antibodies
reacting with biotin (Bio-IgM) and developed an indirect EIA to
quantify their level and assess their seroprevalence. The adverse
effects of biotin IgM on biotinylation-based immunoassays were
assessed, including four inhouse virus IgM EIAs and one
commercial assay. The biotin IgM and streptavidin/avidin were
shown to compete for binding to biotin. The affinities of the biotin
IgM were also determined.
Results
Detection of Biotin Antibodies in Human Sera and
Assessment of Seroprevalence among Adults and
Children
To measure seroreactivities against biotin among the general
population, an indirect IgM EIA (Bio-EIA) was set up with
biotinylated BSA as antigen. The EIA OD values of 612 serum
samples from 459 adults were plotted in a bar chart (Figure 1): 553
(90%) samples showed values ,0.1 OD units, whereas 26 (4.2%)
showed values .0.2. To confirm the EIA results, western blot
(WB) was employed, as shown in Figure 2 with representative
samples from each patient group. Positive WB signals were
uniformly observed among the samples with EIA reactivities $0.3
OD units, but were rare among those with reactivities below 0.3.
No signal against unbiotinylated BSA was seen with any of the
samples.
Among the 144 adults comprising students and staff, 4 (2.8%)
had biotin IgM and among 316 senior individuals, 10 (3.2%), as
shown in Table 1. From four of the latter, 1–3 week follow-up sera
were available, and all maintained the biotin IgM signal at
invariant intensity. However, the institute staff member who was
initially positive with OD 2.5 in Bio-EIA lost his IgM during
follow-up of six months, without IgG seroconversion. Among 678
samples from 349 children aged 1–12 years (median 2.5; mean
3.2), only one serum sample was positive. Overall, based on our
assays, the seroprevalence of biotin IgM among adults of all ages
was 3.0%, and was substantially lower (0.3%) among children. Of
note, none of the Bio-IgM-positive samples contained IgG
Figure 1. Biotin IgM indirect EIA. (A) Layout of biotin IgM indirect
EIA (Bio-EIA). (B) The distribution of EIA absorbance values of 612 adults’
serum samples of Group 1 and Group 2. Five-pointed star: HRP
conjugates.
doi:10.1371/journal.pone.0042376.g001
Figure 2. Correspondence between EIA absorbances and western blot reactivities. In each blot the left lane contains biotinylated BSA, and
the right lane contains nonbiotinylated BSA. In lower right corner is the blot treated with the protein stain Ponceau S red.
doi:10.1371/journal.pone.0042376.g002
Table 1. Biotin IgM seroprevalence in the general population.
Cohort Subjects no. Positive subjects no. Seropositivity
Adults 144 4 2.8%
Seniors 316 10 3.2%
Children 349 1 0.3%
doi:10.1371/journal.pone.0042376.t001
Biotin IgM Antibodies in Human Blood
PLoS ONE | www.plosone.org 2 August 2012 | Volume 7 | Issue 8 | e42376
antibodies against biotin; neither did any of the 110 Bio-IgM-
negative samples analyzed (data not shown).
Assessment of the Biotin Antibody Effect on IgM
Antibody Assays
To assess whether the biotin IgM affects biotinylation-based
antiviral IgM assays, all available Bio-IgM-positive serum
samples were examined by four inhouse virus IgM EIAs of m-
capture format [MCV, Trichodysplasia-spinulosa polyomavirus
(TSV), human bocavirus 1 (HBoV), parvovirus B19 (B19V)]
and by one commercial kit (B19V EIA of Biotrin). In Figure 3A,
16 adults’ sera with Bio-EIA ODs between 0.312 and 1.118,
showed in inhouse-EIA ODs of 0.202–0.674 for MCV, of
0.045–0.338 for TSV, of 0.013–0.072 for HBoV and of 0.066–
0.309 for B19V, and ODs of 0.078–0.171 in the commercial
B19V EIA. In contrast, four samples (one senior sample and
three of the four B19V-IgM false positive samples) with Bio-EIA
reactivities exceeding OD 3, showed elevated reactivities in all
assays (Figure 3B). With each of these sera, the ODs in MCV
EIA exceeded those in the other EIAs. According to the cutoff
values for each assay, among those 20 serum samples, the
numbers of respective samples that were positive, negative, and
at borderline range in each assay were 17, 3, 0 for MCV, 7, 11,
2 for TSV, 4, 16, 0 for HBoV, 7, 12, 1 for B19V (inhouse), and
1, 18, 1 for B19V (Biotrin).
Competition between IgM and Streptavidin/avidin for
Binding to Biotin
Serum samples, 9 Bio-IgM positive and 9 negative, were
applied in a m-capture EIA (inhouse EIA, Figure 4), and therein
tested with one of three different antigens: biotinylated MCV
virus like particles (MCVLPs), biotinylated BSA and soluble
biotin. In Figure 4B-I, the Bio-IgM-positive samples showed
positive IgM results with biotinylated MCVLPs at a minimum
amount of 5 ng/well, with a dose-dependent increase in
reactivity. Correspondingly, they also yielded positive IgM
results (Figure 4B-II) with biotinylated BSA at 10 mg/well or
higher, but negative results with soluble biotin regardless of
concentration (Figure 4B-III). By comparison, none of the Bio-
IgM-negative sera showed any reactivity using as antigen
biotinylated MCVLPs, biotinylated BSA or souble biotin.
Competition experiments (Figure 5A and B) were performed
with samples reactive with biotinylated MCVLPs in a m-capture
IgM EIA (MCV inhouse EIA). With two Bio-IgM-positive sera,
the reactivities were blocked dose-dependently by increasing
concentrations of soluble biotin, but not by non-biotinylated
MCVLPs. Correspondingly, with two MCV-IgM-positive sera,
the reactivities were blocked by MCVLPs, but not by biotin.
Furthermore, as shown in Figure 5C and D, the Bio-EIA
reactivities of positive sera were efficiently abolished by
coincubation with avidin dose-dependently with increasing
concentrations.
Affinity Determination (Half-maximal Inhibitory
Concentration IC50)
The binding specificity and affinity of biotin IgM antibodies
were further studied by competition experiments (Figure 6A), in
which the binding of a given Bio-IgM to solid-phase biotinylated
BSA was measured in the presence of homologous soluble biotin
and heterologous vitamin B5 (Pantothenic acid, Sigma-Aldrich,
P2250). In Figure 6B, the reactivities of six serum samples were
inhibited by biotin, but not by vitamin B5. In Figure 7, with six
serum samples diluted, the binding of biotin IgM to biotinylated
BSA was inhibited in a dose-dependent fashion, with IC50s
ranging from 2.161023 to 1.761024 mol/L.
Discussion
We report for the first time the occurrence of IgM antibodies
to biotin in humans of the general population. The biotin IgM
shown here interacts non-covalently with biotin, differently from
previously reported biotin-binding immunoglobulins (BBI),
which were formed by biotin covalently bound to the constant
region of IgM or IgG [19,20]. For seroprevalence determina-
tion, we developed an EIA for these antibodies. The cutoff for
positivity in our assay was set according to immunoblot results,
whereby we found a seroprevalence of 3% among Nordic
adults. Existing data on occurrence of human antibodies to
vitamins are scarce except for anti-vitamin D IgG antibodies
that have been observed at a low prevalence in patients with
autoimmune diseases [21]. As autoantibodies do occur also in
healthy people, e.g. rheumatoid factor (RF) in 1–3% of the
general population [22–24], the possibility that the biotin IgM
has an association with autoimmunity deserves to be explored in
the future. On the other hand, with an essential role in
Figure 3. Effect of biotin IgM on biotinylation-based virus IgM
EIAs. (A) The distribution of reactivities measured by four inhouse virus
IgM EIAs and one commercial kit; serum samples containing moderate
or low levels of biotin IgM (EIA absorbance ,1.200). The dotted lines
indicate median absorbance values, and bars represent interquartile
values. Absorbance values were analyzed using one-way ANOVA for
overall comparison (P,0.0001), followed by Tukey-Kramer HSD test for
pairwise comparison. #P,0.0001 compared to all the others;
**P,0.0001, *P,0.05. (B) The reactivities with four serum samples
containing high levels of biotin IgM (EIA absorbance.3.000). The cutoff
values for positivity and negativity are: MCV 0.260 and 0.207, TSV 0.240
and 0.194, HBoV 0.167 and 0.136, B19 0.220 and 0.171, B19 Biotrin 0.342
and 0.279.
doi:10.1371/journal.pone.0042376.g003
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metabolism, biotin can exist in the human body in various
forms, such as biotinylated carboxylases and metabolites [1].
Another interesting possibility stems from the fact that biotin
only accounts for half of the total avidin-binding substances in
human plasma, as biotin metabolites that originate from cellular
oxidation account for the rest [25,26]. As those metabolites in
molecular structure resemble biotin [1], it is possible that the
biotin IgM is derived from an immune response to these
metabolites, possibly due to an imbalance in biotin metabolism.
Since biotin IgM was initially found in a serum sample with
false positivity in our inhouse IgM assay, we determined the
susceptibility of several assays to it. We found that, serum
samples with high levels of biotin IgM affected adversely all
virus IgM assays, while samples containing low levels of the
antibody showed low interference level in most assays. Indeed,
biotin IgM was shown to be an important contributor to false
positivities in virus IgM assays. Moreover, our results showed
that among m-capture IgM assays for four different viruses, the
effects of biotin IgM were different. The MCV IgM EIA was
more susceptible than the others. This difference may depend
on the conformation of viral particles or their degree of
biotinylation. Thus, at least two ways emerge to limit the effect
of the biotin IgM: one is to optimize the amount of biotin in
VLP trimming, and the other is to employ an appropriate
borderline zone upon setting up the cutoffs according to the
false reactivities derived from biotin IgM.
We did study in detail whether the different effects of biotin
antibodies on IgM assays would relate with the conformations
of the biotinylated antigens. As MCV VLPs were more
susceptible than BSA, it is possible that ordered supramolecular
assemblies are more susceptible than isolated polypeptides. Of
note, biotin itself in solution never gave a positive signal. To
account for this, three possibilities existed: (a) the soluble biotin
did not bind to the biotin IgM captured on the plate; (b) the
IgM-attachment abolished biotin’s ability to bind to streptavidin;
(c) IgM would bind the long spacer arm (LC) of biotinylation
reagent (Sulfo-NHS-LC-Biotin) instead of the biotin itself. To
find the answer, we performed competition assays with soluble
biotin in MCV IgM EIA. The fact that soluble biotin displaced
biotinylated MCV VLPs without causing positive results itself,
proved that biotin could not bind IgM antibodies and
streptavidin simultaneously and that the binding was specific
for the biotin itself and not the spacer arm. As avidin is
a natural constituent in human’s diet and binds to biotin
similarly as streptavidin does [12], we performed competition
assays with avidin, which confirmed that IgM and streptavidin/
avidin compete with each other for binding to biotin. As biotin
is a small molecule (244Da), IgM and streptavidin/avidin
probably share on biotin the same binding site. On the other
hand, as avidin can prevent the intestinal absorption of biotin
[3,7,8], it is tempting to speculate a similar function for the
biotin IgM in blood. Indeed, whether the biotin IgM can
Figure 4. Interaction of biotin IgM with biotin-containing antigens in m-capture IgM EIAs. Serum samples containing or lacking biotin IgM
were applied in m-capture IgM EIAs including (I) Biotinylated MCVLPs (at concentrations of 100 ng, 10 ng, 5 ng, 1 ng/100 mL), (II) Biotinylated BSA (at
concentrations of 20 mg, 10 mg, 1 mg, 100 ng/100 mL) or (III) Soluble biotin (at concentrations of 20 mg, 10 mg, 1 mg, 100 ng/100 mL). The reactivities
were plotted in boxplot. Five-pointed star: HRP conjugates. P: positive group comprising nine Bio-IgM positive sera. N: negative group comprising
nine Bio-IgM-negative sera.
doi:10.1371/journal.pone.0042376.g004
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prevent biotin uptake by tissues or cells is an exciting topic for
further study.
We furthermore assessed the binding strength of biotin IgM by
measuring IC50 [27]. The observed affinity level of 1023–
1024 mol/L is similar to that of many natural antibodies with
their respective antigens [28–32]. An interesting possibility is that
the biotin IgM belongs to the group of germ line-encoded
immunoglobulins generated without known antigenic stimulation.
Most natural antibodies do belong to the IgM class and are
presumed to be driven by endogenous host antigen [28,30,33]. As
biotin has the ability to interact with host proteins [1,2,34], the
resulting complexes might drive the production of these antibodies
toward the ligand. However, the biotin IgM seemed specific, as it
in our study did not react with vitamin B5, a vitamin so closely
related to biotin that it can inhibit the intestinal absorption of the
latter [35].
Since our study cohorts are residents in Finland, it would be
worthwhile to investigate biotin antibodies in non-Finnish
populations. On the other hand, as our seroprevalence data are
not population-based, they do not necessarily disclose the precise
prevalence of biotin IgM antibodies even among the Finnish
population. Nevertheless, the finding of biotin IgM in human sera
opens a new venue for research of vitamin-directed immunity. The
potential effects of these antibodies on human health call for
investigation. These antibodies might adversely affect the uptake
of biotin from circulation, or might help in clearance of excessive
biotin and its metabolites in blood.
Figure 5. Competition assays. (A) In inhouse MCV IgM EIA, biotinylated MCV VLPs (10 ng/100 mL) were mixed with increasing concentrations of
either unbiotinylated MCV VLPs or soluble biotin and added onto the m-capture plates (100 mL/well). (B) The upper figures show two serum samples
positive for biotin IgM; the lower figures show two serum samples positive for MCV IgM. (C and D) In Bio-EIA, four samples positive for biotin IgM
were coincubated with avidin and applied to the assay. Five-pointed star: HRP conjugates.
doi:10.1371/journal.pone.0042376.g005
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Materials and Methods
Ethics Statement
The study protocol was reviewed and approved by the Ethics
Committees of Turku and Helsinki University Hospitals. Written
informed consent was obtained from all participants. If senior
participant was unsure about the consent, or he/she was assessed
by a geriatrician to have reduced capacity to consent, a written
consent was obtained from the next of kin. If participants were
children, consent was obtained from parents or guardians.
Samples
The occurrence of biotin IgM antibodies was determined in 612
serum samples from two groups of adults and 678 samples from
children. The first group, referred to as ‘‘Adults’’ comprised 144
sera from University students and our Institute staff, and the
second group, ‘‘Seniors’’, comprised 468 sera from 316 senior
citizens (mean age 82 years, range 70–100). All senior citizens
were in-patients of Turku City Hospital and participated to Virel
study which aims to investigate detailed molecular virus etiology in
the elderly and its links to illness severity and long-term outcome.
The last group, ‘‘Children’’, comprised sera from 349 children at
sampling age of 1–12 years (median 2.5; mean 3.2), which were
previously studied for MCV and TSV primary infection [36,37].
In addition, four serum samples observed to cause false reactivities
in our inhouse assay for B19V IgM due to biotin antibodies, were
also included in the present study but omitted from the calculation
of seroprevalence.
Biotin IgM Indirect Enzyme Immunoassay
An indirect EIA was set up for detection of biotin IgM in
human serum samples (Bio-EIA, Figure 1A). For use as antigen,
bovine serum albumin (BSA) (Sigma-Aldrich, A7906) was
biotinylated by using the EZ-Link Sulfo-NHS-LC-Biotinylation
kit (Pierce, Rockford, IL.) in accordance with the manufacturer’s
instructions, and dialyzed against PBS. Strips of microtiter wells
were placed in lockwell frames (Nunc-ImmunoTM Modules and
Frames), and coated with 200 ng/well of biotinylated BSA in
PBS for 2.5 hours at 37uC. After 5 washes with PBS containing
0.05% Tween-20 (PBST), the wells were blocked in 5% BSA in
PBS for 30 min at 37uC, followed by a rinse. The serum
samples diluted 1:100 in PBST were applied in duplicate
(100 ml/well) for 60 min at room temperature in a rocking
(400 rpm) EIA incubator. After washes with PBST, polyclonal
rabbit anti-human IgM-horseradish peroxidase conjugate (Da-
koCytomation, Glostrup, Denmark) diluted 1:1,000 in 3% BSA/
PBST, was added to each well (100 ml), and incubated for
60 min. After washes, orthophenylene diamine and H2O2 were
added, the reaction was stopped after 25 min with 0.5 M
H2SO4, and the absorbances at 492 nm were recorded. For
background reactivity, a BSA-EIA was set up by coating the
plates with unbiotinylated BSA and performed as above.
In cutoff determination, all sera yielding OD ,0.15 units in
Bio-EIA were considered negative, and the samples with higher
OD were re-examined by both Bio-EIA and BSA-EIA; and the net
OD was obtained by subtraction of BSA-EIA background.
Samples with net OD $0.3 were considered positive, those with
net OD ,0.2 were considered negative, and those with net OD
between 0.2 and 0.3 were considered borderline.
Western Blot Analysis
For detection of biotin IgM by immunoblot, 1 mg/lane of
biotinylated BSA (Bio-BSA) or BSA was separated by 10% SDS-
PAGE and transferred onto nitrocellulose membranes (Whatman
Protran BA 85), blocked in 5% BSA in Tris buffered saline
containing 0.1% Tween 20 (TBST) for 30 min at room
temperature (RT). The serum samples diluted 1:100 or 1:50 in
5% BSA/TBST were kept on the blots at 4uC overnight. After
washing with TBST, a polyclonal rabbit peroxidase-conjugated
anti-human IgM (DakoCytomation, Glostrup, Denmark) diluted
1:20,000 in 5% BSA/TBST was applied for 1 hour at RT. After
washes, the blots were developed using the SuperSignal West Dura
Extended Substrate Detection kit (Pierce, Rockford, IL.) and
exposed on X-ray films (Fuji Super RX).
IgM Enzyme Immunoassay
m-capture EIAs were performed in analogy to our many
antiviral IgM EIAs (inhouse EIAs) [15–18]. Briefly, serum
Figure 6. Competition assays on Bio-IgM-positive serum samples. In Bio-EIA, sera preincubated with increasing concentrations of either
soluble biotin (5, 10, 20, 50, 75 mg/100 mL) or vitamin B5 (25, 50, 75 mg/100 mL) for 1 hr at RT, and applied into the plates (100 mL/well). The
reactivities declined to undetectable levels upon serum preincubation with biotin, but not with vitamin B5.
doi:10.1371/journal.pone.0042376.g006
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samples diluted 1:200 in PBST were applied in duplicate into
wells of plates coated with goat anti-human IgM (Cappel/ICN
Biomedicals) for 60 min at room temperature. After washes, the
biotinylated antigens were applied and incubated for 45 min at
37uC. Then the plates were treated with horseradish peroxidase-
conjugated streptavidin (Dako, Glostrup, Denmark) at 1:12,000
in PBST containing 0.5% BSA for 45 min at 37uC, followed by
orthophenylene diamine and H2O2 for 15 min at 37uC. In
competition assay, the biotinylated antigen was mixed with
a nonbiotinylated one, and added into the plates (Figure 5A).
Affinity Determination
Based on the Bio-EIA, a competition assay was set up to
measure biotin IgM affinity [27,29,38,39]. Briefly, the sera were
diluted for an OD of 0.4 to 1.2 and incubated with increasing
concentrations of soluble biotin (Sigma-Aldrich, B4501) over
night, to reach equilibrium. The mixtures were then transferred
into EIA plates in five replicates and the amount of antibody
bound to the solid phase was measured as described above. The
mean values were plotted in a graph, yielding a fitting curve by
a nonlinear regression program (GraphPad Prism). The IC50
was then calculated from the curve, corresponding to affinity
[27,39].
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